To assess these anti-PD-(L)1 Myeloid signature results in the context of the immunosuppressive myeloid genes observed in the HD-IL2 cohort in this study, the relative expression levels of the genes reported in the IMmotion150 phase II trial (28) are presented in Fig. 4C–E for the pretreatment RCC specimens of both the HD-IL2 and the anti-PD1 cohort. The gene discussed is IL2; the disease is renal cell carcinoma.